For the Inventor, By the Inventor

Enter assignee name

Santa Monica, CA, United States of America

Kite Pharma, Inc.

USPTO Granted Patents = 41

CIPO Patents = 1

EPO Patents = 11

Trademarks = 24

Forward Citations = 86

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Stuart A Sievers (14 out of 15 patents)

Jed Wiltzius (11 out of 12 patents)

Adrian I Bot (8 out of 8 patents)

4. Jed J W Wiltzius (7 out of 7 patents)

5. Steven A Rosenberg (6 out of 139 patents)

6. Ruben Alvarez Rodriguez (6 out of 7 patents)

7. Jeffrey S Wiezorek (5 out of 5 patents)

8. William Go (5 out of 5 patents)

9. Rajul Jain (5 out of 5 patents)

10. James Noble Kochenderfer (5 out of 28 patents)

11. Jonathan Belk (4 out of 17 patents)

12. Peter Emtage (3 out of 12 patents)

13. John M Rossi (2 out of 2 patents)

14. Armen Mardiros (2 out of 5 patents)

15. Arianne Perez Garcia (2 out of 2 patents)

Core Competencies:

Chimeric Antigen Receptors

T Cell Therapy

Antigen Binding Molecules

Chimeric Polypeptides

T Cell Functionality

Prostate Cancer Treatments

Tumor Microenvironment

Soluble MHC Molecules

Modified Chimeric Receptors

BCMA Binding Molecules

CD70 Binding Molecules

Humanized Antigen-Binding Domains

41 patents: Sort by Forward Citations

1. D1102621 - Cassette rack (2025-11-18),

2. 12459979 - Modified chimeric antigen receptors and methods of use (2025-11-04),

3. 12458654 - Methods of conditioning patients for T cell therapy (2025-11-04),

4. 12454563 - Immune cell function (2025-10-28),

5. 12404305 - Chimeric polypeptides and uses thereof (2025-09-02),

6. 12357646 - Chimeric antigen receptor T cell therapy (2025-07-15),

7. 12337035 - TACI binding molecules (2025-06-24),

8. 12331315 - Chimeric antigen receptor (2025-06-17),

9. 12280119 - Chimeric transmembrane proteins and uses thereof (2025-04-21),

10. 12252701 - Chimeric antigen receptor T cell therapy (2025-03-18),

11. 12202909 - Antigen binding molecules specific for an anti-CD19 scFV (2025-01-21),

12. 12180292 - CD70 binding molecules and methods of use thereof (2024-12-31),

13. 12156887 - Chimeric receptor T cell treatment using characteristics of the tumor microenvironment (2024-12-03),

14. 12152251 - T cells with improved functionality (2024-11-26),

15. 12109235 - TGF-beta receptors and methods of use (2024-10-08),

Kite Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer immunotherapies. Their vision is to make a significant and transformational impact on cancer patients by advancing the field of cell therapy. Kite Pharma is dedicated to unlocking the power of the immune system through their engineered cell therapies, with a particular emphasis on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. They strive to bring life-saving treatments to patients with various types of cancers, utilizing their expertise in research, development, and manufacturing of cell therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

41 Patents

#7 in Santa Monica, CA

#1,930 in California

#8,166 in US

#16,217 in the World

Santa Monica, CA, United States of America

Kite Pharma, Inc.

Forward Citations = 86

49 inventors:

Stuart A Sievers (14 out of 15 patents)

Jed Wiltzius (11 out of 12 patents)

Adrian I Bot (8 out of 8 patents)

4. Jed J W Wiltzius (7 out of 7 patents)

5. Steven A Rosenberg (6 out of 139 patents)

Please report any incorrect information to support@idiyas.com

Loading…